237 related articles for article (PubMed ID: 15756684)
1. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy.
Sato K; Kimura S; Segawa H; Yokota A; Matsumoto S; Kuroda J; Nogawa M; Yuasa T; Kiyono Y; Wada H; Maekawa T
Int J Cancer; 2005 Aug; 116(1):94-9. PubMed ID: 15756684
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic human peripheral blood-derived γδT cells kill glioblastoma cell lines: implications for cell-based immunotherapy for patients with glioblastoma.
Nakazawa T; Nakamura M; Park YS; Motoyama Y; Hironaka Y; Nishimura F; Nakagawa I; Yamada S; Matsuda R; Tamura K; Sugimoto T; Takeshima Y; Marutani A; Tsujimura T; Ouji N; Ouji Y; Yoshikawa M; Nakase H
J Neurooncol; 2014 Jan; 116(1):31-9. PubMed ID: 24062140
[TBL] [Abstract][Full Text] [Related]
3. [Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma].
Li Z; Tang J; Sun L; Ye Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):6-9. PubMed ID: 23294710
[TBL] [Abstract][Full Text] [Related]
4. Isopentenyl pyrophosphate secreted from Zoledronate-stimulated myeloma cells, activates the chemotaxis of γδT cells.
Ashihara E; Munaka T; Kimura S; Nakagawa S; Nakagawa Y; Kanai M; Hirai H; Abe H; Miida T; Yamato S; Shoji S; Maekawa T
Biochem Biophys Res Commun; 2015 Aug; 463(4):650-5. PubMed ID: 26047704
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate.
Sugai S; Yoshikawa T; Iwama T; Tsuchiya N; Ueda N; Fujinami N; Shimomura M; Zhang R; Kaneko S; Uemura Y; Nakatsura T
Int J Oncol; 2016 May; 48(5):1794-804. PubMed ID: 26936487
[TBL] [Abstract][Full Text] [Related]
6. Vγ9Vδ2 T cells and zoledronate mediate antitumor activity in an orthotopic mouse model of human chondrosarcoma.
Sun L; Li Y; Jiang Z; Zhang J; Li H; Li B; Ye Z
Tumour Biol; 2016 Jun; 37(6):7333-44. PubMed ID: 26676633
[TBL] [Abstract][Full Text] [Related]
7. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.
Nagamine I; Yamaguchi Y; Ohara M; Ikeda T; Okada M
Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555
[TBL] [Abstract][Full Text] [Related]
8. Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model.
Yuasa T; Sato K; Ashihara E; Takeuchi M; Maita S; Tsuchiya N; Habuchi T; Maekawa T; Kimura S
Cancer Immunol Immunother; 2009 Apr; 58(4):493-502. PubMed ID: 18682944
[TBL] [Abstract][Full Text] [Related]
9. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
[TBL] [Abstract][Full Text] [Related]
10. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
11. Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2.
Li W; Kubo S; Okuda A; Yamamoto H; Ueda H; Tanaka T; Nakamura H; Yamanishi H; Terada N; Okamura H
J Immunother; 2010 Apr; 33(3):287-96. PubMed ID: 20445349
[TBL] [Abstract][Full Text] [Related]
12. [Cancer immunotherapy using gammadelta T cells ex vivo expanded by bisphosphonate].
Kimura S
Clin Calcium; 2008 Apr; 18(4):499-505. PubMed ID: 18379032
[TBL] [Abstract][Full Text] [Related]
13. Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells.
Muraro M; Mereuta OM; Carraro F; Madon E; Fagioli F
Cell Immunol; 2007 Oct; 249(2):63-72. PubMed ID: 18163982
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells.
Poccia F; Gioia C; Martini F; Sacchi A; Piacentini P; Tempestilli M; Agrati C; Amendola A; Abdeddaim A; Vlassi C; Malkovsky M; D'Offizi G
AIDS; 2009 Mar; 23(5):555-65. PubMed ID: 19238075
[TBL] [Abstract][Full Text] [Related]
15. [Amplification of γδ T cells in PBMCs of healthy donors and osteosarcoma patients stimulated by zoledronate].
Li ZX; Sun LL; Cheng RL; Sun ZW; Ye ZM
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Aug; 28(8):822-4. PubMed ID: 22863589
[TBL] [Abstract][Full Text] [Related]
16. Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid.
Idrees AS; Sugie T; Inoue C; Murata-Hirai K; Okamura H; Morita CT; Minato N; Toi M; Tanaka Y
Cancer Sci; 2013 May; 104(5):536-42. PubMed ID: 23387443
[TBL] [Abstract][Full Text] [Related]
17. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma.
Mariani S; Muraro M; Pantaleoni F; Fiore F; Nuschak B; Peola S; Foglietta M; Palumbo A; Coscia M; Castella B; Bruno B; Bertieri R; Boano L; Boccadoro M; Massaia M
Leukemia; 2005 Apr; 19(4):664-70. PubMed ID: 15744346
[TBL] [Abstract][Full Text] [Related]
18. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
[TBL] [Abstract][Full Text] [Related]
19. Nano-technology based carriers for nitrogen-containing bisphosphonates delivery as sensitisers of γδ T cells for anticancer immunotherapy.
Hodgins NO; Wang JT; Al-Jamal KT
Adv Drug Deliv Rev; 2017 May; 114():143-160. PubMed ID: 28694026
[TBL] [Abstract][Full Text] [Related]
20. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo.
Benzaïd I; Mönkkönen H; Stresing V; Bonnelye E; Green J; Mönkkönen J; Touraine JL; Clézardin P
Cancer Res; 2011 Jul; 71(13):4562-72. PubMed ID: 21646473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
